BMBF awards 16M€ to support German epigenome program initiative

NewsGuard 100/100 Score

The German Ministry for Research and Education (BMBF) will support the German epigenome program initiative "DEEP" with a budget of 16M€ over 5 years. DEEP will be the official German contribution to the world wide operating International Human Epigenome Consortium (IHEC). The DEEP program will be coordinated by Prof. Dr. Jörn Walter, Saarland University. DEEP forms a network of 21 German expert groups for interdisciplinary epigenome research.

DEEP will generate 70 reference epigenome maps of major primary cell/tissue types in normal and diseased states exclusively using NGS technologies. The scientific program focusses on metabolic and inflammatory diseases such as adipositas, fatty liver disease, bowel disease and rheumatic arthritis. DEEP combines strong experimental and bioinformatics expertise in epigenomics. The goal is to generate high quality reference epigenomes which will be deposited in public repositories coordinated by IHEC. The DEEP epigenome program will be flanked by functional model studies using mouse and human cell systems. This combined program will produce new functional insights in the molecular processes of complex systemic diseases.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel immune cell therapy may be a promising strategy for combating HBV infection